08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
08-06-2012 23:47:00

J&J to Record $600 Million Charge Tied to Outstanding Lawsuits

Relateret indhold
Relateret debat
16 maj - 
We can deliver Financial service/instruments(BG/SBLC/MT..
16 maj - 
FDA NEWS RELEASE For Immediate Release: Dec. 4, 2013 Me..

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:47 ET (21:47 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Mærsk: EU ventes at sige god for tilbud i monopolsag - citat

28-06-2016 16:10:06
EU konkurrencemyndigheder har i sinde at acceptere et tilbud fra blandt andet A.P. Møller-Mærsk samt 14 andre rederier.Det skal sætte stop for en fem år lang un..

Mærsk/Sydbank: Løfter til "køb" efter tab af Qatar-kontrakt

28-06-2016 13:34:38
Sydbank har fået et mere positivt syn på A.P. Møller-Mærsk-aktien efter tabet af Maersk Oils kontrakt i Qatar. Banken anbefaler nu "køb" mod tidligere "hold".De..

Aktier/middag: TDC topper bredt comeback

28-06-2016 11:28:44
De danske aktier laver tirsdag - i takt med de øvrige europæiske af slagsen - et comeback efter to dage med blodrøde markeder.Sidste uges folkeafstemning i Stor..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Stabilisering i vente - skidt nyt fra Mærsk
2
Nu mødes chokerede ledere for at redde stumperne af EU
3
Mærsk/Sydbank: Løfter til "køb" efter tab af Qatar-kontrakt
4
Dublin, Paris, Luxemburg og Frankfurt vil tage over for London
5
Storbritannien får endnu et hak i kreditværdigheden

Relaterede aktiekurser

Johnson & Johnson 117,83 1,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. juni 2016 20:37:01
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160627.1 - EUROWEB3 - 2016-06-28 20:37:01 - 2016-06-28 20:37:01 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x